Arjuna has revealed plans to invest more than 10% of its turnover in clinical research to explore the health benefits of a number of new, healthy ingredients to be launched this year – including a $1.5m investment in studies on turmeric curcumin alone.
Extensive research is being conducted in universities and institutes in India, Australia, Italy, the US and Japan into BCM-95, Arjuna’s all-natural curcumin. The India-based company has already commissioned 12 clinical studies of curcumin to examine its effect on a range of conditions, including depression, cancer, Alzheimer’s disease and others.
And the company will present the most recent clinical study results on curcumin for mental health disorders at the Vitafoods Europe conference in Geneva this May.
Arjuna joint managing director Benny Anton said: “We differentiate our turmeric curcumin through a practice of extensive research and development. BCM-95 is the most researched bioavailable curcumin on the market, with a majority share in the US.”
“Arjuna meets the new European 2015/1933 PAH regulation that sets maximum levels of polycyclic aromatic hydrocarbons (PAHs) in food supplements. This bioactive ingredient is clean of pesticides and heavy metals. Arjuna invested in the most advanced quality control equipment to meet the new EU regulations, and to ensure all products are clean and safe. The growing global demand for curcumin, and consumer expectations of pure formulations, encouraged Arjuna to develop a clean, GMO-free ingredient that consumers can trust.”
© FoodBev Media Ltd 2024